FoRx Therapeutics是一家抗癌药物研发商，旨在开发用于癌症治疗的化合物。FoRx专注于对涉及DNA复制压 力的关键分子靶标进行药物治疗，这是开发靶向抗癌药的新方法。近日，FoRx Therapeutics获得5000万美元A轮融资，EQT Life Sciences、辉瑞Pfizer、Novartis Venture Fund、M ...

Funding to support Phase 1 clinical development of best-in-class PARG inhibitor candidate FORX-428 FORX-428 is potential new treatment option for patients whose cancers are resistant to, or have ...

FORX-428 is potential new treatment option for patients whose cancers are resistant to, or have become resistant to, PARP inhibitors Initial data expected in mid-2026 from open-label Phase 1 study in ...

Forx Therapeutics AG presented data on their PARG inhibitor – FORX-428 – for the treatment of cancer. FORX-428 is a highly potent, selective and orally bioavailable PARG inhibitor that showed strong ...